title: Increased toxicity when fibrates and statins are administered in combination--a metabolomics approach with rats.
abstract: Combination therapies with fibrates and statins are used to treat cardiovascular diseases, because of their synergistic effect on lowering plasma lipids. However, fatal side-effects like rhabdomyolysis followed by acute renal necrosis sometimes occur. To elucidate biochemical changes resulting from the interaction of fibrates and statins, doses of 100 mg/kg fenofibrate, 50mg/kg clofibrate, 70 mg/kg atorvastatin and 200 mg/kg pravastatin as well as combinations thereof were administered to Crl:Wi(Han) rats for 4 weeks. Plasma metabolome profile was measured on study days 7, 14 and 28. Upon study termination, clinical pathology parameters were measured. In a separate experiment plasmakinetic data were measured in male rats after 1 week of drug administration in monotherapy as well as in combinations. Lowering of blood lipid levels as well as toxicological effects, like liver cell degradation (statins) and anemia (fibrates) and distinct blood metabolite level alterations were observed in monotherapy. When fibrates and statins were co-administered metabolite profile interactions were generally underadditive or at the utmost additive according to the linear mixed effect model. However, more metabolite levels were significantly altered during combination therapy. New effects on the antioxidant status and the cardiovascular system were found which may be related to a development of rhabdomyolysis. Accumulation of drugs during the combination therapy was not observed.
authors.affiliation: BASF SE, Experimental Toxicology and Ecology, Z 470, 67056 Ludwigshafen, Germany.
authors.forename: V
authors.initials: V
authors.lastname: Strauss
authors.forename: W
authors.initials: W
authors.lastname: Mellert
authors.forename: J
authors.initials: J
authors.lastname: Wiemer
authors.forename: E
authors.initials: E
authors.lastname: Leibold
authors.forename: H
authors.initials: H
authors.lastname: Kamp
authors.forename: T
authors.initials: T
authors.lastname: Walk
authors.forename: R
authors.initials: R
authors.lastname: Looser
authors.forename: A
authors.initials: A
authors.lastname: Prokoudine
authors.forename: E
authors.initials: E
authors.lastname: Fabian
authors.forename: G
authors.initials: G
authors.lastname: Krennrich
authors.forename: M
authors.initials: M
authors.lastname: Herold
authors.forename: B
authors.initials: B
authors.lastname: van Ravenzwaay
mesh_terms: D000818:Animals; D001772:Blood Cell Count; D001835:Body Weight / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination / Q000009:adverse effects; D004435:Eating / Q000187:drug effects; D058607:Fibric Acids / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D008297:Male; D055432:Metabolomics / Q000379:methods; D051381:Rats; D053719:Tandem Mass Spectrometry
chemical_list: D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents